<DOC>
	<DOCNO>NCT00351520</DOCNO>
	<brief_summary>Cutaneous leishmaniasis parasitic skin lesion cause different specie Leishmania transmit bite infected sand fly . Leishmaniasis exist 88 country , pentavalent antimonials ( sodium stibogluconate meglumine antimoniate ) use standard treatment disease last 80 year . Pentavalent antimonials available injectable , painful , toxic , affordable moreover always effective even sometimes several course treatment . Many different modality use treat disease little success . Miltefosine drug recently show effective treatment cutaneous leishmaniasis Colombia . The molecular mechanism contribute effectiveness clearly understood . Only well design , randomize clinical trial precisely evaluate efficacy therapeutic modality cutaneous leishmaniasis . In study efficacy oral treatment miltefosine 2.5 mg per Kg body weight 4 week compare standard treatment intramuscular injection 60 mg/kg/day glucantime 2 week ACL parasitologically proven patient . At 8 week initiation treatment patient group receive miltefosine respond treatment treated standard intramuscular injection 60 mg/kg/day glucantime 2 week . The clinical trial carry accord International approve GCP ( Good Clinical Practice ) guide line .</brief_summary>
	<brief_title>Efficacy Trial Oral Miltefosine Comparison With Glucantime Treatment ACL Caused L. Tropica</brief_title>
	<detailed_description>Leishmaniasis cause least 20 different specie Leishmania transmit bite infected sand fly . Leishmaniasis endemic 88 country , mostly develop one . Leishmaniasis incidence rate 1.5-2 million mostly cutaneous form , 350 million population risk major health problem endemic country Iran endemic cutaneous leishmaniasis ( CL ) , anthroponotic CL ( ACL ) cause L. tropica Zoonotic CL ( ZCL ) cause L. major 1 , 2 . Pentavalent antimonials ( sodium stibogluconate meglumine antimoniate ) use standard treatment leishmaniasis 80 year . Pentavalent antimonials parentrally available , painful , toxic , affordable endemic area moreover always effective even sometimes several course treatment , recently resistance Leishmania antimonials report . Other modality physical , immunological , topical systemic therapy use controversial result 3,4 . Miltefosine , phosphocholine analogue affect cell-signaling pathway membrane synthesis 5 . Almost strain mice resistant L. major L. mexicana infection , ressitant strain L. major infection induces transient self heal lesion similar human CL accompanies Th1 response susceptible BALB/c mouse infect L. major induces Th2 type immune response infection develop systemic form disease similar human Kala azar eventually every mouse succumed disease . Miltefosine recently show effective treatment visceral leishmaniasis ( VL ) cause L. donovani New World CL cause L. vianna panamensis Colombia 6-8 . The result open-label , multicenteric , phase II trial different dose oral miltefosine ( 4 6 week ) patient VL cause L. donovani India show cure rate 95 % ( 120 patient show initial parasitologic cure relapse see 6 patient ) 6 . In another randomized , open trial India , VL patient receive miltefosine orally ( approximately 2.5 mg/kg daily 28 day ) , amphotericin B ( 1 mg/kg , every day 30 day ) end treatment , parasitological cure rate 100 % 6 % patient receive miltefosien show relapse 6 month 7 . Phase I-II open dose escalate trial miltefosine American CL Colombia show oral miltefosine safe cure rate 66 94 % different dose 8 . In placebo-controlled trial miltefosine Colombia Guatemala , American CL cause L. v. panamensis treat miltfosine ( 2.5 mg/kg per day orally 28 day ) , end teatment period , per-protocol cure rate miltefosine group 91 % placebo group 38 % 9 . The molecular mechanism contribute antileishmanial activity miltefosine clearly understood apparently effect immune response macrophage since immunodefient mouse SCID mouse deficient mouse still susceptible miltefosine action 10-12 . It show miltefosine induces nuclear DNA condensation apoptosis-like death L. donovani 12-14 . The controversy obsereved report efficacy different modality CL mainly due consider self healing nature disease design study . Factors variations susceptibility different Leishmania specie various drug difference criterion use evaluate efficacy drug important . Although reliable report available efficacy glucantime treatment ACL cause L. tropica surely efficacy poor , resistant L. tropica glucantime exist ( manuscript submit ) . Only well design , randomize clinical trial precisely evaluate efficacy therapeutic modality CL . In study efficacy oral treatment miltefosine 2.5 mg per Kg body weight 4 week compare standard treatment intramuscular injection 60 mg/kg/day glucantime 2 week ACL parasitologically proven patient . At 8 week initiation treatment patient group receive miltefosine respond treatment treated standard intramuscular injection 60 mg/kg/day glucantime 2 week . The clinical trial carry accord GCP ( Good Clinical Practice ) guide line . Study area/setting : ( Instructions : describe area set study conduct . This description cover detail relevant study topic ) Study site : There two site ACL high incidence rate Iran ; one Mashad , Khorasan second one Bam , Kerman , incidence rate ACL Bam increase earthquake accord recent survey currently underway . The trial carry either site enough number ACL patient , also complete recruitment faster trial could carry site . 6.2 Study subject : ( Instructions : eligibility exclusion criterion study subject ) I ) Inclusion criterion : ) Parasitologically proven case CL base positive smear and/or culture ; b ) Otherwise healthy subject basis medical history , physical examination result blood test ( complete blood count [ CBC ] , liver function test [ LFT ] renal function test [ RFT ] ) ; c ) Age 12-50 year ; ) body weight 40 kilogram ; e ) willing participate study sign inform consent ( patient his/her parent/guardian case young 18 year ) . II ) Exclusion criterion : ) Pregnant lactate woman ; b ) Duration lesion 6 month ; c ) Number lesion 5 ; ) Lesion ( ) bacterial supperinfection e ) History full course standard treatment ( antimonials ) ; f ) History allergy glucantime ; g ) Serious systemic illness ( judged physician ) ; h ) Participation drug trial last 60 day . III ) Withdrawal criterion : ) A serious adverse event occur ; b ) Withdrawal consent . Withdrawn case treat accord investigator opinion beneficial patient cost . All withdrawn patient evaluate final analysis ( intent-to-treat analysis ) . IV ) Treatment : In phase III , randomize open trial , subject meet inclusion criterion trial randomly allocate two group accord randomization list . One group treat 2.5 mg/kg body weight oral miltefosine second group treat intramuscular injection 60 mg/kg/day glucantime 2 week . The oral miltefosine tablet deliver patient day 0 , 7 , 14 21 . A write instruction sheet give include patient , patient instruct contact research team appearance symptom suggest severe side effect ( intractable diarrhea and/or vomiting , symtoms liver , kidney hematopoietic system dysfunction . A copy randomization list code keep WR office . Eight week initiatin treatment , patient receive oral miltefosine active lesion treat intramuscular glucantime injection ( 60mg/kg/day 14 day ) . v ) Follow-up : Every include patient visit 1 , 2 , 3 , 4 , 8 24 week initiation treatment . The flow chart attach . 6.3 Study design : ( Instructions : mention type study design eg cross-sectional , case-control , intervention study , etc.. ) This trial open randomize clinical trial GCP guide line . The Center academic staff well qualify train GCP nationally internationally , several clinical trial therapeutic vaccine development complete group.. v ) Follow-up : The patient visit 1 , 2 , 3 , 4 , 8 24 week initiation treatment . The flow chart attach . 6.3 Study design : ( Instructions : mention type study design eg cross-sectional , case-control , intervention study , etc.. ) This study randomize , open clinical trial GCP guide line . The Center academic staff well qualify train GCP nationally internationally complete several clinical trial therapeutic vaccine efficacy trial GCP guide line . Cutaneous leishmaniasis : Skin lesion clinically suspicious parasitologically proven direct smear and/or culture . The study area endemic ACL portion Leishmania isolate use charecterization identification use monoclonal antibody PCR technique . Clinical cure : The primary clinical efficacy parameter complete re-epithelization lesion disappearance induration ( without scar ) . No parasitological evaluation do clinically cured lesion . Clinical improvement : Reduction size ulcer induration . Treatment failure : No change increase size induration ulcer . Relapse : Reappearance lesion site periphery cure lesion consider relapse . Parasitological cure : Negative smear culture end treatment follow period regard parasitological cure . 1 . Leishmaniasis . Tropical Disease Research , Progress 1995-96 . Thirteenth Programme Report , WHO , Geneva , 1997 . 2 . Dowlati Y. Cutaneous leishmaniasis : clinical aspect . Clin Dermatol 1996 ; 14:425-31 . 3 . Dowlati Y . Treatment cutaneous leishmaniasis ( old world ) . Clin Dermatol 1996 ; 14:513-7 . 4 . Berman JD . Human leishmaniasis : clinical , diagnostic , chemotherapeutic development in.the last 10 year . Clin Inf Dis 1997 ; 24:684-703 . 5 . Schmidt-Ott R , Klenner T , Overath P , Aebischer T. Topical treatment hexadecylphosphocholine ( Miltex ) efficiently reduce parasite burden experimental cutaneous leishmaniasis . Trans R Soc Trop Med Hyg . 1999 ; 93 ( 1 ) :85-90 6 . Jha TK. , Sundras S , Thakur CP et al . Miltefosine , oral agent , treatment indian viceral leishmaniasis . N Engl J Med 1999 ; 341:1795-800 . 7 . Sundar S , Jha TK , Thakur CP , et al Oral miltefosine Indian visceral leishmaniasis . N Engl J Med . 2002 ; 347 ( 22 ) :1739-46 . 8 . Soto J , Toledo J , Gutierrez P , Nicholls RS , Padilla J , Engel J Fischer C , Voss A , Berman J , Treatment American Cutaneous Leishmaniasis Miltefosine , Oral Agent . Clin . Infec . Dis . 2001 ; 33 : e57-e61 9 . Soto J , Arana BA , Toledo J , et al . Miltefosine new world cutaneous leishmaniasis Clin Infect Dis . 2004 ; 38 ( 9 ) :1266-72 . 10 . Leonard R , Hardy J , van Tienhoven G , et al . Randomized , double-blind , placebo-controlled , multicenter trial 6 % miltefosine solution , topical chemotherapy cutaneous metastasis breast cancer . J Clin Oncol . 2001 ; 19 ( 21 ) :4150-9 . 11 . Escobar P , Yardley V , Croft SL . Activities Hexadecylphosphocholine ( Miltefosine ) , AmBisome , Sodium Stibogluconate ( Pentostam ) Leishmania donovani Immunodeficient scid Mice.Antimicrob.Agents Chemotherapy , 2001 ; : , Vol . 45 , No:61872-1875 12 . Murray HW , Delph-Etienne S , Visceral Leishmanicidal Activity Hexadecylphosphocholine ( Miltefosine ) Mice Deficient T Cells Activated Macrophage Microbicidal Mechanisms . J. Infec Dis . 2000 ; 181:795-799 13 . Paris C , Loiseau PM , Bories C , Breard J. Miltefosine induce apoptosis-like death Leishmania donovani promastigotes . Antimicrob Agents Chemother . 2004 ; 48 ( 3 ) :852-9 . 14 . Verma NK , Dey CS . Possible mechanism miltefosine-mediated death Leishmania donovani . Antimicrob Agents Chemother . 2004 ; 48 ( 8 ) :3010-5 .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>Parasitologically proven case CL base positive smear and/or culture Otherwise healthy subject basis medical history , physical examination result blood test ( seem necessary physician ) Age 1260 year Willing participate study sign inform consent ( patient his/her parent/guardian case young 18 year ) . Pregnant lactate woman Duration lesion 6 month Number lesion 4 Ulcer size great 4 cm large diameter History full course standard treatment ( antimonials ) History allergy Glucantime Serious systemic illness ( judged physician ) Participation drug trial last 60 day</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Anthoponotic Cutaneous leishmaniasis</keyword>
	<keyword>Glucantime</keyword>
	<keyword>Miltefosine</keyword>
</DOC>